z-logo
open-access-imgOpen Access
Increased awareness enhances physician recognition of the role of smoking in chronic pancreatitis
Author(s) -
Thiruvengadam Muniraj,
Dhiraj Yadav,
Judah Abberbock,
Samer Alkaade,
Stephen T. Amann,
Michelle A. Anderson,
Peter A. Banks,
Randall E. Brand,
Darwin L. Conwell,
Gregory A. Coté,
Chris E. Forsmark,
Timothy B. Gardner,
Andrés Gelrud,
Nalini M. Guda,
Mark Lewis,
Joseph Romagnuolo,
Bimaljit S. Sandhu,
Stuart Sherman,
Vikesh K. Singh,
Adam Slivka,
Gong Tang,
David C. Whitcomb,
C. Mel Wilcox
Publication year - 2020
Publication title -
vestnik kluba pankreatologov
Language(s) - English
Resource type - Journals
ISSN - 2077-5067
DOI - 10.33149/vkp.2020.03.04
Subject(s) - medicine , etiology , pancreatitis , risk factor , smoking cessation , protective factor , pathology
Background: We have previously reported that physicians under-recognize smoking as a chronic pancreatitis (CP) risk factor. We hypothesized that availability of empiric data will influence physician recognition of this relationship. Methods: We analyzed data from 508 CP patients prospectively enrolled in the North American Pancreatitis Study-2 Continuation and Validation (NAPS2-CV) or NAPS2-Ancillary (AS) studies (2008–2014) from 26 US centers who self-reported ever-smoking. Information on smoking status, physician-defined etiology and identification of smoking as a CP risk factor was obtained from structured patient and physician questionnaires. We compared how often physician identified smoking as a CP risk factor in NAPS2-CV/NAPS2-AS studies with NAPS2-original study (2000–2006). Results: Enrolling physician identified smoking as a risk factor in significantly (all p< 0.001) greater proportion of patients in NAPS2-CV/AS studies when compared with NAPS2-original study among ever (80.7 vs. 45.3%), current (91.3 vs. 53%), past (60.3 vs. 30.2%) smokers, in those who smoked ≤1 pack/day (79.3 vs. 39.5%) or ≥1 packs/day (83 vs. 49.8%). In multivariable analyses, the enrolling physician was 3.32–8.49 times more likely to cite smoking as a CP risk factor in the NAPS2-CV/NAPS2-AS studies based on smoking status and amount after controlling for age, sex, race and alcohol etiology. The effect was independent of enrolling site in a sub-analysis limited to sites participating in both phases of enrollment. Conclusions: Availability of empiric data likely enhanced physician recognition of the association between smoking and CP. Wide-spread dissemination of this information could potentially curtail smoking rates in subjects with and those at risk of CP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here